Introduction
After Trousseau's description of thrombophlebitis as a complication of pancreatic cancer in the 19 th century, the notion that increased expression of TF underlies the relation between coagulation and cancer has become generally accepted. Full-length TF (flTF) is a 47 kDa membrane-bound glycoprotein that is present on subendothelial cells 1 . In the classic concept of coagulation, it is thought that endothelial disruption leads to exposure of flTF to the blood stream. Exposed flTF can bind to its natural ligand factor VII (FVII), which then becomes activated FVII (FVIIa). The thus formed flTF:FVIIa complex converts factor X (FX) to factor Xa (FXa) and FXa in turn activates prothrombin leading to formation of thrombin (factor IIa). Thrombin subsequently activates platelets and converts fibrinogen into fibrin, two essential components of a stable hemostatic plug 1 .
The primary function of subendothelial flTF is to serve as a hemostatic envelope surrounding the vasculature. However, under certain conditions the expression of flTF is induced in monocytes and endothelial cells. flTF is also often expressed on cancer cells and the tumor vasculature 2 , and flTF-bearing microparticles can become shed by these cells 3 .
These flTF-bearing microparticles are important contributors to the thrombotic phenotype in cancer patients 3 .
The flTF:FVIIa complex also influences pathways that do not lead to blood coagulation, but rather activate cell-bound protease-activated receptors (PARs) that are of importanceduring the inflammatory and angiogenic response to injury 4 , Furthermore, a soluble variant of flTF, known as alternatively spliced TF (asTF), stimulates angiogenesis independent of FVIIa 5;6 .
In this review, we discuss the current knowledge of the role of the various TF isoforms in the modulation of cancer that comes from both experimental and patient-based studies.
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Oncogenic events drive flTF expression
flTF expression in cancer is the result of well-defined upstream events that occur during the process of oncogenic transformation (see figure 1 ). " In colorectal cancer (CRC) mutations of both the K-ras proto-oncogene and p53, leading to loss of p53 function, result in a constitutive activation of the mitogen activated protein kinase (MAPK) and phosphatidylinositol-3' kinase (PI3K) signaling pathways, thus leading to enhanced TF expression 7 . In vivo experiments confirmed that the K-ras and p53 mutations in CRC are indeed primarily responsible for flTF upregulation 7 . This is in agreement with the finding that in CRC patients mutations of K-ras, p53 are associated with flTF expression in tumors 8 .
Amplification of epidermal growth factor receptor (EGFR) expression and a constitutively active mutant form of EGFRvIII have also been shown to modulate flTF expression in cancer cells. EGFRvIII overexpression in glioma cells results in flTF expression. Restoration of the tumor suppressor gene PTEN in these cells, which leads to inhibition of the PI3 kinase and MAPK pathways, downregulates EGFR-dependent flTF expression 9 . Moreover, endometrial cancer cell lines display enhanced flTF levels in an EGFdependent fashion 10 , and inhibition of EGFR signaling diminishes flTF expression in vulva carcinoma cells constitutively expressing the EGFRvIII mutant 11 .
Recent studies in medullo-blastoma cell lines indicate that Src family kinases stimulate an induction of flTF expression through both the scatter factor/hepatocyte growth factor (SF/HGF) and as a result of a mutation in the c-MET oncogene, while flTF expression via the HGF:c-MET axis elicits an anti-apoptotic response and provides resistance to chemotherapeutical agents 12 .
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In vivo experiments in a murine xenograft model with human vulvar carcinoma cells show that epithelial-to-mesenchymal transition (EMT), and the concomitant inactivation of Ecadherin, result in further EGFR-induced flTF expression. These events lead to increased production of vascular endothelial growth factor (VEGF), thus enhancing the angiogenic potential of cancer cells 11 .
Transforming growth factor-β (TGF-β) is an essential cytokine for EMT to occur, and is co-expressed with flTF in tumor cells and tumor stromal cells 15 , suggesting the production of TGF-β production as a critical upstream event in upregulation of flTF in tumors. EMT also contributes to the generation of what are currently regarded cancer stem cells. Cancer stem cells form a subpopulation of tumor cells that fuels tumor growth, and has functional properties distinct from other cancer cell populations, e.g. cancer stem cells may transdifferentiate to vascular cells 16 . Support for this notion comes from studies that show that CD133-positive cancer stem cells derived from a vulva carcinoma cell line, display enhanced flTF-dependent coagulant activity 17 . Nevertheless, it remains unclear whether cancer stem cells derive their phenotype from expression of flTF or that expression of flTF is merely associated with the cancer stem cell phenotype..
Hypoxia may also modulate flTF expression by cancer cells. Analysis of human glioma specimens shows that flTF expression is highest in cells that surround sites of necrosis in hypoxic pseudopalisades 18 . Hypoxia-driven flTF expression is not dependent on hypoxiaactivated factor HIF1α, but rather on the early growth response gene-1 19 .
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TF isoforms and their cellular effects on cancer
Binding of FVIIa to flTF results in a series of signaling events that regulates a broad range of cellular responses such as: 1) gene transcription; 2) cell survival; and 3) cytoskeletal changes, that are required for a cell to adequately respond to its local environment 4 (figure 2).
Despite the structural homology between flTF and interferon receptors 20 , flTF:FVIIa signaling differs substantially from classical interferon receptor signaling. Rather than actively recruiting the JAK/STAT complex to the intracellular domain of flTF, flTF:FVIIa typically triggers signaling via PAR2. PARs form a four-member family of 7-transmembrane domain cellular receptors that are activated by proteolytic cleavage of the extracellular amino terminus. This event leads to exposure of a tethered ligand that folds back to the second extracellular loop resulting in receptor activation. PAR1 is the archetypical thrombin receptor, but is also cleaved by other proteases such as plasmin, FXa, matrix metalloproteinase-1 and activated protein C. flTF:FVIIa, FXa, trypsin and tryptase are able to activate PAR2, whereas PAR4 is activated by thrombin and plasmin 4 . In mouse models, PAR3 has been found to serve as a cofactor for PAR4 21 , but recent data suggest that human PAR3 may also be activated directly by thrombin 22 . Upon activation, PARs couple to heterotrimeric G-proteins after which further signaling events are initiated 4 .
Signaling of flTF:FVIIa via PAR2 elicits calcium transients and activation of the major members of the MAPK family, p44/42, p38 and c-Jun N-terminal kinase (JNK). In addition, Src-like kinases, PI3 kinase, the Jak/STAT pathway and the Rho GTPases Rac1 and Cdc42 are activated, culminating in cell survival and cytoskeletal rearrangements 4 . Activation of both the MAPK and PI3 kinase pathways contributes to a pro-malignant transcriptional For personal use only. on October 24, 2017. by guest www.bloodjournal.org From program and stimulates oncogenic protein synthesis 4 . flTF:FVIIa-mediated PAR2 activation also leads to the production of pro-angiogenic factors such as VEGF, Cyr61, VEGF-C, CTGF, CXCL1, and IL8, as well as of immunological modulators such as granulocyte-macrophage colony stimulating factor (GM-CSF or CSF2) and macrophage colony stimulating factor (M-CSF or CSF1) [23] [24] [25] . Although PAR1 signaling induces a similar series of proteins in breast cancer cells, the activation of the flTF:VIIa:PAR2 axis appears to elicit a more efficient production of these angiogenesis and immune regulators 25 In conclusion, TF isoforms, FVII, PAR2 and integrins have pleiotropic effects on cellular processes that are important in cancer biology at the level of cell survival, as well as the interaction of cells with their environment, in particular angiogenic events. The apparent lack of coagulant activity of asTF further underlines that the effects of TF isoforms can occur through coagulation-independent mechanisms. In the following paragraph, we will examine how these effects contribute to cancer progression in in vivo cancer models. promote primary tumor growth through PAR1 activation, increasing evidence supports that its role in metastasis is more potent 50 . This concept recently found even more support in a report on the pro-metastatic phenotype of mice with a thrombomodulin mutant with decreased affinity for thrombin 51 . Further evidence for a prominent role of downstream coagulation activation in metastasis comes from experiments in genetically modified mice that either lack platelets, PAR4 or fibrinogen. Mice with either of these genetic modifications were protected from metastasis, which provides evidence that metastasis is facilitated by thrombin-activated platelets via PAR4 52 . Thus, flTF on tumor cells initiates PAR2 dependent signaling with subsequent effects on tumor growth, and simultaneously induces thrombin generation that facilitates metastasis.
TF isoforms in cancer: evidence from experimental studies
At present, mechanistic insight into the role of asTF in cancer biology is sparse. asTFproducing pancreatic cancer cells yield larger tumors in comparison with asTF negative cells upon xenografting 6 . asTF is believed to augment angiogenesis by acting as an integrinactivating agent 5 , but the exact mechanism remains unclear. Future studies with specific targeting of either asTF or flTF in constitutively asTF-expressing cancer cell lines will increase the knowledge on asTF in cancer biology.
In 
TF isoforms in human cancer
In this section, we will discuss whether the concepts described above, find support in studies that are primarily aimed at finding correlation between expression of TF isoforms and pathological and clinical parameters. We will not discuss observational studies that examine flTF expression in human cancer without describing associations with clinical and pathological parameters due to space limitations. A comprehensive overview of the studies that we selected for this review is provided in 61 , pancreatic 63 To date the expression of asTF in relation to clinicopathological characteristics has only been studied in NSCLC and these studies reveal a correlation between high asTF mRNA levels and advanced tumor stage, whereas low levels of flTF mRNA relate to less advanced stages of cancer progression 40 . In another study, high asTF mRNA levels conferred an 10H10 was only investigated in early stages of tumorigenesis, more research is necessary to study its effects after the angiogenic switch has taken place. Another approach could be the use of RNA interference to target tumor flTF, as RNAi has proven to be beneficial in mouse experiments 7 . Indeed, pharmacological modalities are available for tumor-specific delivery of RNAi 88 , but again, the response to these anti-tumorigenic therapies in murine models of early tumorigenesis, and its translation to human flTF-expressing tumors, remains uncertain.
Several studies on the efficacy of flTF-targeting in cancer have been undertaken or are still ongoing. The nematode flTF:VIIa inhibitor recombinant NAPc2 has been studied in colorectal cancer 89 , however the company suspended the trial, so that it is unclear whether the inhibition of tumor growth found in mice 42 can be translated to humans. Currently, two other potential flTF-targeting drugs are under investigation in clinical studies, ALT-836 (Altor Bioscience ©), a TF-inhibiting antibody, and PCI-27483 (Pharmacyclics ©), a small FVIIa inhibiting molecule. The efficacy of ALT-836 is currently investigated in solid tumors in combination with gemcitabine 90 . PCI-27483 at present is tested in a similar set-up, but this study is limited to pancreatic cancer patients 91 . Both studies aim to target both the coagulant and signaling effects of flTF in tumor biology and the results from these studies will be helpful for deciding whether flTF-targeting is viable option for future treatment of cancer and cancer-related thrombosis.
Despite promising results, many questions remain before flTF-targeted therapies will become available for clinical application. For example, it is unclear what the effect on hemostasis will be in a patient population already displaying a severely unbalanced coagulation, although no bleeding effects have been reported in mouse studies. The 10H10 antibody may be attractive, since it leaves the coagulant properties of flTF unaffected, but Moreover, the coagulant properties of flTF promote cancer progression through enhancing the metastatic potential. Therefore, targeting the coagulant function flTF may be necessary to really provide new therapeutic means. In contrast to flTF, asTF has no proven function in physiology yet, and a role for asTF in cancer biology is becoming more evident. This apparent cancer-specificity puts asTF forward as a new cancer target. Specific antibodies to the unique C-terminus of RNAi to the exon 4-6 boundary offer opportunities for a specific blockade, however, the effect of interfering with asTF in cancers is still speculative. Use of flTF-mediated approaches for targeting tumoricidal drugs or infarcting tumor vasculature, may be hampered by off-target effects as well, as other parts of the vasculature may express flTF. Phototherapy is perhaps most promising in circumventing such unwanted effects, since it only exerts its effects by controlled exposure to laser light, which may be highly specific thanks to improving tumor imaging modalities.
Delivery of anti-tumor drugs to sites of enhanced TF expression

Conclusions
During the last decades, it has become increasingly clear that flTF not only has a prominent role in the etiology of cancer-related thrombosis, but also that TF isoforms display For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Table 1 
. Overview of studies on TF expression in human cancer
Cancer type, source, number of studies tumors, TF as detected by immunohistochemistry, detection methods, and the study's main findings regarding TF are listed. IHC, immunohistochemistry; IHF, immunohistofluorescence; MVD, microvessel density; TF, Tissue Factor; asTF, Alternatively Spliced Tissue Factor.
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